Chicago、ILにおける肺がんの臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、肺がんに関する41件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 他1件
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 他1件
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
被験者募集中第1/2相
- University of Illinois Hospital & Health Sciences System ( Site 0044), Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
被験者募集中第3相
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
被験者募集中第3相
- Northwestern University, Chicago
- University of Illinois, Chicago
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Northwestern University, Chicago
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- University of Illinois Cancer Center, Chicago
- Center for Care and Discovery, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
被験者募集中第3相
- University of Illinois Chicago, Chicago
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
A Registry for People With Lung Cancer
被験者募集中観察研究
- Rush University Medical Center (Data collection only), Chicago
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
被験者募集中第2相
- Research Site, Chicago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- Rush University Medical Center, Chicago
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
被験者募集中第1/2相
- University of Chicago Comprehensive Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
被験者募集中第3相
- University of Illinois Hospital and Health Sciences Systems, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Northwestern University, Chicago
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
被験者募集中第3相
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
被験者募集中第1相
- Xencor Investigative Site, Chicago
- Xencor Investigative Site, Chicago
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
被験者募集中第2相
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
被験者募集中
- Northwestern University, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
被験者募集中第1/2相
- University of Chicago, Chicago
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
被験者募集中健康なボランティア歓迎
- University of Illinois at Chicago, Chicago
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
被験者募集中第2相
- University of Chicago Medicine, Chicago
Lung Cancer Screening in High-risk Black Individuals
被験者募集中健康なボランティア歓迎
- University of Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- The University of Chicago Comprehensive Cancer Center, Chicago
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
被験者募集中観察研究
- Advocate Illinois Masonic Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
被験者募集中観察研究
- University of Chicago, Chicago
Olaparib in Patients With HRD Malignant Mesothelioma
被験者募集中第2相
- University of Chicago Medical Center, Chicago
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
被験者募集中観察研究
- Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital), Chicago
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
被験者募集中観察研究
- Northwestern University, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
被験者募集中第2相
- Northwestern University, Chicago
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- New York City, NY60件の研究
- Los Angeles, CA45件の研究
- Washington, DC41件の研究
- Arlington, VA41件の研究
- Nashville, TN40件の研究
- Baltimore, MD40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
- Seattle, WA33件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん58件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肥満症41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌33件の研究
- 心不全31件の研究
- 過体重28件の研究
- 頭頸部扁平上皮癌26件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。